Sharemaestro Newsreel

AHG|Akso Health Group|Price:1.510|Chg%:+0.060

Akso Health Group's fundamentals are weak, but it has high growth potential. The stock is considered fairly valued and institutional ownership is low. The stock price is currently trading sideways between support and resistance levels, making it suitable for range-bound swing trading, though a …

YI|111 Inc|Price:3.730|Chg%:-0.190

This article provides a detailed financial overview of 111 Inc (YI), an investment holding company operating an integrated online and offline healthcare platform. It highlights the company's stock performance, key financial figures, and a TradingKey Stock Score indicating stable fundamentals with high growth potential, …

Cardinal Health, Inc. Revenue Breakdown – NYSE:CAH

Henry Schein, Inc. (HSIC) stock price, news, quote and history

This Yahoo Finance page provides comprehensive information on Henry Schein, Inc. (HSIC), including its current stock price, historical data, recent news, and key financial metrics. The article details the company's business segments, performance overview compared to the S&P 500, analyst insights, and valuation measures. …

Cosmos Health Inc (COSM) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Cosmos Health Inc (COSM), outlining its major individual and institutional holders. It provides a breakdown of shareholder types, institutional holdings over several quarters, and recent shareholder activity with changes in their stake. Key shareholders include Grigorios Siokas, …

HSIC|Henry Schein Inc|Price:85.470|Chg%:+0.940

This article provides a comprehensive financial overview of Henry Schein Inc (HSIC), detailing its stock performance, key financial indicators, and earnings reports. It includes an income statement, balance sheet, and cash flow statement, alongside a BUY analyst rating. The data covers quarterly and annual …

Henry Schein Inc (HSIC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Henry Schein Inc (HSIC), focusing on its regional contributions. As of April 6, the company's total revenue was $13.19 billion, with 68.99% ($9.10 billion) generated in the United States and 31.01% ($4.09 billion) from international markets. Information …

Cencora (COR) Stock Could Be 39% Below Fair Value

Cencora (COR) stock appears undervalued, with its Discounted Cash Flow (DCF) intrinsic value estimated at $502 per share, suggesting a 39.3% discount from its current share price of $305.06. Additionally, Cencora's P/E ratio of 23.3x is lower than the healthcare industry average of 25.5x …

Cardinal Health (CAH) Stock May Trade Above Fair Value Following Home Care Deals

Cardinal Health's stock has seen a significant 320% return over the past five years, raising valuation concerns, with recent analysis suggesting it trades above its fair value. Despite strong performance and recent acquisitions in home care sectors, the stock only passes two out of …

A4EQAC Bond Risk Profile

This page provides a risk profile for the Cencora, Inc. 4.6% 13-FEB-2033 A4EQAC bond, available on Gettex. It outlines key metrics for credit risk assessment, including security level, inflation protection, and issuer rating. Additionally, the page mentions access to exclusive analyst ratings for bonds.

111 Inc (YI) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of 111 Inc (YI), noting its current valuation score is 9.73, placing it 8th out of 155 in the Pharmaceuticals industry. The company's P/E ratio is reported as -34.19, which is significantly below its recent high and above …

Ecolab Gears Up to Report Q2 Results: How to Play the Stock?

Ecolab (ECL) is set to release its second-quarter 2026 results on July 28, with expectations of significant organic growth driven by value pricing, strong demand, and momentum in high-growth areas like Global High-Tech and Life Sciences. Despite anticipated pressure on margins from elevated commodity …

Can GE HealthCare Sustain Growth in Q2 Amid Persistent Cost Headwinds?

GE HealthCare (GEHC) is expected to report healthy revenue growth for the second quarter of 2026, driven by global demand for imaging equipment and strong performance in Pharmaceutical Diagnostics. However, profitability is likely to remain under pressure due to elevated inflation in various input …

Here's Why You Should Add Cencora Stock to Your Portfolio Now

Cencora (COR) is positioned for growth due to its strong U.S. Healthcare Solutions business and new product launches, despite facing competitive pressures. The company is actively expanding in specialty pharmaceuticals and strengthening its supply chain, supported by favorable industry forecasts. However, challenges include revenue …

Will Baxter's Q2 Results Continue to Reflect Operational Headwinds?

Baxter International Inc. (BAX) is scheduled to release its second-quarter 2026 results on July 30, with expectations of continued operational headwinds impacting performance. The company anticipates revenue decline and a significant drop in earnings per share due to manufacturing inefficiencies, inflationary pressures, and issues …

Insider Buyers Lose Additional US$75k As Synergy CHC Dips To US$2.7m

Insiders at Synergy CHC Corp. have seen their US$79.6k investment, made at an average price of US$2.85 per share, decrease to US$4.7k due to a recent 14% stock drop. Despite this loss, the article highlights that the CEO and Chairman, Jack Ross, previously bought …

Ohio’s Cardinal Health company acquires two medical supply companies for $360 million

Cardinal Health, based in Dublin, Ohio, has acquired AdaptHealth Corp.’s Diabetes Health business and Strive Medical for a combined $360 million. This acquisition will add over 245,000 patients to Cardinal Health’s at-Home Solutions platform, expanding its direct-to-patient healthcare services, particularly in diabetes management and …

Cardinal Health leans into CGMs, urology supplies

Cardinal Health is strategically expanding its presence in the continuous glucose monitors (CGMs) and urology supplies markets through key acquisitions, aiming for long-term growth. The company recently announced plans to acquire AdaptHealth's diabetes business for $235 million and Strive Medical for $125 million, building …

Cencora stock holds steady as investors await fresh numbers

Cencora Inc. stock remains focused on its existing financial metrics, with revenue, earnings, and margin profile influencing its valuation. However, the available search results lack fresh market or report figures, making it impossible to create a source-grounded article about new developments. The article explicitly …

How Investors May Respond To McKesson (MCK) Dividend Hike And Portfolio Reshaping Strategy

McKesson Corporation announced a 15% dividend increase, marking its tenth consecutive year of dividend hikes, alongside a strategy to streamline its portfolio and expand in oncology services. This move aims to provide steady cash returns while enhancing the business mix, with forecasts projecting significant …

CAH|Cardinal Health Inc|Price:225.940|Chg%:+5.400

Cardinal Health Inc. (CAH) currently shows strong fundamentals and high growth potential, with its valuation considered fairly valued within the Pharmaceuticals industry. Analysts have rated it as a "Buy" with a target price of $254.08, suggesting an 11.89% upside. While institutional ownership remains very …

Do Cardinal Health’s New Home-Health Deals Reshape the Bull Case for CAH?

Cardinal Health recently announced the acquisition of AdaptHealth’s Diabetes Health business and Strive Medical for approximately $360 million, expanding its at-Home Solutions in diabetes and urology. These deals, coupled with raised profit guidance, aim to strengthen Cardinal Health's position in home-based care and improve …

Here's What to Expect From Cardinal Health's Next Earnings Report

Cardinal Health (CAH) is expected to announce its fiscal fourth-quarter earnings for 2026 on August 11, with analysts predicting a profit of $2.42 per share, a 16.4% increase year-over-year. The company has consistently beaten EPS estimates and its stock has significantly outperformed the S&P …

Henry Schein | 4: Statement of changes in beneficial ownership of securities-Officer Popeck Thomas C

This document appears to be a Form 4 filing from Henry Schein, detailing a statement of changes in beneficial ownership of securities for an officer named Popeck Thomas C. As a Form 4, it indicates transactions involving company stock by an insider. The specific …

McKesson Director James H. Hinton Awarded 277 Restricted Stock Units Under 2022 Equity Plan

McKesson Corporation director James H. Hinton was granted 277 restricted stock units on July 22, 2026, as part of the company's 2022 Stock Plan. These units vest immediately, with share delivery deferred until Hinton leaves the board. This transaction is part of McKesson's standard …

Cardinal Health, Inc. Stock 12‑Month Price Target Raised to $255.6, Implies 16% Upside

Analysts have raised the average 12-month price target for Cardinal Health, Inc. (CAH) stock to $255.6, up from $254.27. This new target suggests a potential upside of approximately 16% from its July 22 closing price. The consensus rating among 21 analysts remains a "Buy," …

MCKESSON CORP : CITIGROUP RAISES TARGET PRICE TO $1000 FROM $945

Citigroup has raised its target price for McKesson Corp (MCK.N) to $1000 from $945. This update reflects an analyst's revised outlook on the pharmaceutical distribution company's stock. The information was provided by Reuters.

Are Investors Undervaluing Henry Schein (HSIC) Right Now?

Henry Schein (HSIC) appears undervalued based on several key valuation metrics and a strong Zacks Rank. The company boasts a Zacks Rank #2 (Buy) and a Value grade of A, with P/E, P/B, P/S, and P/CF ratios all favorable compared to industry averages and …

Perrigo Company plc (PRGO) Stock Price, News, Quote & History

This Yahoo Finance page provides detailed stock information for Perrigo Company plc (PRGO), including its current stock price, recent trading activity, key financial metrics, and performance over various periods. It also offers an overview of the company's business segments and products, analyst insights, and …

Pharma Pulse: Cardinal Health Bulks Up Home Care, Trump Unveils Phased Generics Tariffs

Cardinal Health expanded its home care business with two acquisitions totaling $360 million, focusing on diabetes health and urology to strengthen its direct-to-patient services. Separately, President Trump announced a phased tariff schedule for generic drugs, initiating with zero tariffs until August 2026, escalating to …

COSM|Cosmos Health Inc|Price:0.206|Chg%: +0.006

Cosmos Health Inc. (COSM) is trading at $0.200 per share with a market capitalization of $8.21 million. The company's fundamentals are considered stable with high growth potential, and its valuation is seen as fairly valued within the Pharmaceuticals industry. Institutional ownership is high, though …

McKesson Director Kathleen Wilson-Thompson Receives 277 Shares via 2022 Stock Plan Grant on July 22, 2026

McKesson Corporation director Kathleen Wilson-Thompson acquired 277 shares of common stock on July 22, 2026, as per a regulatory filing. The shares were purchased at $814.04 each, increasing her direct beneficial ownership to 578 shares. This transaction provides transparency into insider trading at the …

Cardinal Health acquires the Diabetes Health business of Conshohocken’s AdaptHealth

Cardinal Health has announced the acquisition of AdaptHealth’s Diabetes Health business and Strive Medical for a total of approximately $360 million in cash. These transactions are designed to accelerate Cardinal Health's at-Home Solutions strategy, expanding its presence in diabetes management and urology supply. The …

Cencora stock trades steady as specialty distribution scale and recent earnings shape investor view

Cencora stock is trading steadily due to the company's significant scale in specialty pharmaceutical distribution and its recent earnings performance. The article highlights Cencora's role as a major US pharmaceutical distributor, emphasizing its growth in specialty distribution, margin stability, and strategic investments in technology …

COR stock consolidates after strong fiscal 2025 results and guidance update

Cencora Inc. (COR) has reported strong fiscal year 2025 results, with multi-billion dollar revenues and increased adjusted earnings per share, positioning it as a key player in pharmaceutical distribution. The company's guidance for future fiscal periods offers insights into anticipated revenue and EPS, crucial …

Henry Schein Inc. stock outperforms competitors despite losses on the day

Shares of Henry Schein Inc. (HSIC) slipped 1.22% to $84.81 on Wednesday, marking its fourth consecutive day of losses. Despite this decline, the stock outperformed the broader market, as the S&P 500 Index (SPX) fell 0.14% and the Dow Jones Industrial Average (DJIA) fell …